Lexicon Pharmaceuticals (LXRX) Other Non-Current Liabilities (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Other Non-Current Liabilities of $6.4 million for Q1 2026, up 20.33% year-over-year from $5.3 million in Q1 2025, and down 11.05% on a QoQ basis from $7.2 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) has 17 years of Other Non-Current Liabilities data on file, last reported at $6.4 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 20.33% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 20.33% YoY) and the FY2025 annual result came in at $7.2 million, up 3.61% from the prior year.
- Other Non-Current Liabilities fell to $6.4 million in Q1 2026 per LXRX's latest filing, from $7.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $7.5 million in Q3 2025 and bottomed at $1.0 million in Q2 2022.
- The 5-year median for Other Non-Current Liabilities is $5.5 million (2023), against an average of $5.4 million.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities slumped 38.3%; it then soared 447.11% in 2023.
- Tracing LXRX's Other Non-Current Liabilities over 5 years: stood at $5.4 million in 2022, then dropped by 2.93% to $5.3 million in 2023, then surged by 31.51% to $6.9 million in 2024, then rose by 3.61% to $7.2 million in 2025, then dropped by 11.05% to $6.4 million in 2026.
- Per Business Quant, the three latest LXRX Other Non-Current Liabilities figures stand at $6.4 million (Q1 2026), $7.2 million (Q4 2025), and $7.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Lexicon Pharmaceuticals | 872.52 Mn | 701.87 Mn | 20.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.38 Mn |
| Dec 31, 2025 | 7.17 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Jun 30, 2025 | 5.20 Mn |
| Mar 31, 2025 | 5.30 Mn |
| Dec 31, 2024 | 6.92 Mn |
| Sep 30, 2024 | 6.67 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Dec 31, 2023 | 5.27 Mn |
| Jun 30, 2023 | 5.48 Mn |
| Mar 31, 2023 | 5.45 Mn |
| Dec 31, 2022 | 5.42 Mn |
| Sep 30, 2022 | 5.44 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 1.19 Mn |
| Sep 30, 2021 | 1.48 Mn |
| Jun 30, 2021 | 1.62 Mn |
| Mar 31, 2021 | 1.72 Mn |
| Dec 31, 2020 | 611,000.00 |
| Sep 30, 2020 | 738,000.00 |
| Jun 30, 2020 | 862,000.00 |
| Mar 31, 2020 | 983,000.00 |
| Dec 31, 2019 | 1.10 Mn |
| Sep 30, 2019 | 1.22 Mn |
| Jun 30, 2019 | 1.33 Mn |
| Mar 31, 2019 | 1.43 Mn |
| Dec 31, 2018 | 238,000.00 |
| Sep 30, 2018 | 252,000.00 |
| Jun 30, 2018 | 265,000.00 |
| Mar 31, 2018 | 279,000.00 |
| Dec 31, 2017 | 292,000.00 |
| Sep 30, 2017 | 303,000.00 |
| Jun 30, 2017 | 313,000.00 |
| Mar 31, 2017 | 559,000.00 |
| Dec 31, 2016 | 805,000.00 |
| Sep 30, 2016 | 2.50 Mn |
| Jun 30, 2016 | 14.04 Mn |
| Mar 31, 2016 | 14.59 Mn |
| Dec 31, 2015 | 14.37 Mn |
| Sep 30, 2015 | 23.52 Mn |
| Jun 30, 2015 | 23.04 Mn |
| Mar 31, 2015 | 23.26 Mn |
| Dec 31, 2014 | 23.54 Mn |
| Sep 30, 2014 | 34.01 Mn |
| Jun 30, 2014 | 34.82 Mn |
| Mar 31, 2014 | 34.02 Mn |
| Dec 31, 2013 | 32.39 Mn |
| Sep 30, 2013 | 37.39 Mn |
| Jun 30, 2013 | 35.26 Mn |
| Mar 31, 2013 | 34.08 Mn |
| Dec 31, 2012 | 32.28 Mn |
| Sep 30, 2012 | 31.09 Mn |
| Jun 30, 2012 | 59.28 Mn |
| Mar 31, 2012 | 57.17 Mn |
| Dec 31, 2011 | 55.15 Mn |
| Sep 30, 2011 | 53.64 Mn |
| Jun 30, 2011 | 51.36 Mn |
| Dec 31, 2010 | 48.78 Mn |